Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.   This agreement is effective 1 March.
 
There are few brands in the prescription world with the equity and recognition of Tritace and Cardizem, which together account for annual sales  in excess of $30 million.  This takes Aspen Australia's annual turnover to over $130 million, and our company to another level.  The addition of these two power brands to our stable of well-known, tried and trusted products is a coup, and will increase our prestige among health professionals.
 
The partnership with Sanofi-Aventis is another milestone for Aspen Pharmacare